ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc (DNTH)

25.82
0.94
( 3.78% )
Updated: 13:33:11

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
25.82
Bid
25.76
Ask
25.93
Volume
127,121
24.40 Day's Range 26.44
0.00 52 Week Range 0.00
Market Cap
Previous Close
24.88
Open
24.55
Last Trade
1
@
25.82
Last Trade Time
13:33:24
Financial Volume
$ 3,248,676
VWAP
25.5558
Average Volume (3m)
-
Shares Outstanding
14,817,762
Dividend Yield
-
PE Ratio
-8.86
Earnings Per Share (EPS)
-2.94
Revenue
2.83M
Net Profit
-43.56M

About Dianthus Therapeutics Inc

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others. Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Dianthus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DNTH. The last closing price for Dianthus Therapeutics was $24.88. Over the last year, Dianthus Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Dianthus Therapeutics currently has 14,817,762 shares outstanding. The market capitalization of Dianthus Therapeutics is $386 million. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -8.86.

DNTH Latest News

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic...

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor...

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25 $389 million of pro forma cash, including $216 million of net proceeds...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRDIGRIID Infrastructure Inc
$ 1.51
(169.64%)
122.15M
ZAPPZapp Electric Vehicles Group Ltd
$ 3.075
(126.10%)
76.01M
MGOLMGO Global Inc
$ 0.7657
(67.04%)
149.82M
RELIReliance Global Group Inc
$ 0.5671
(45.00%)
114.7M
SMXSMX Security Matters Public Company
$ 0.1612
(35.46%)
162.76M
WHLRWheeler Real Estate Investment Trust Inc
$ 2.74
(-82.57%)
124.38k
KAVLKaival Brands Innovations Group Inc
$ 2.895
(-35.67%)
884.77k
TRVNTrevena Inc
$ 0.23975
(-32.35%)
36.81M
MBIOMustang Bio Inc
$ 0.58
(-31.77%)
34.39M
NLSPNLS Pharmaceutics Ltd
$ 0.1906
(-29.43%)
12.53M
NVDANVIDIA Corporation
$ 131.4059
(-3.08%)
324M
NKLANikola Corporation
$ 0.3521
(-26.78%)
182.49M
SMXSMX Security Matters Public Company
$ 0.1612
(35.46%)
162.76M
MGOLMGO Global Inc
$ 0.7657
(67.04%)
149.82M
GRDIGRIID Infrastructure Inc
$ 1.51
(169.64%)
122.15M

Your Recent History

Delayed Upgrade Clock